ATE275968T1 - Mitteln zur behandlung von auto-immun krankheiten - Google Patents

Mitteln zur behandlung von auto-immun krankheiten

Info

Publication number
ATE275968T1
ATE275968T1 AT96922162T AT96922162T ATE275968T1 AT E275968 T1 ATE275968 T1 AT E275968T1 AT 96922162 T AT96922162 T AT 96922162T AT 96922162 T AT96922162 T AT 96922162T AT E275968 T1 ATE275968 T1 AT E275968T1
Authority
AT
Austria
Prior art keywords
treatment
agents
agent
auto
immune diseases
Prior art date
Application number
AT96922162T
Other languages
English (en)
Inventor
Neil Andrew Williams
Timothy Raymond Hirst
Toufic Osman Nashar
Walk University
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol filed Critical Univ Bristol
Application granted granted Critical
Publication of ATE275968T1 publication Critical patent/ATE275968T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96922162T 1995-07-05 1996-07-05 Mitteln zur behandlung von auto-immun krankheiten ATE275968T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513733.7A GB9513733D0 (en) 1995-07-05 1995-07-05 Therapeutic agents
PCT/GB1996/001614 WO1997002045A1 (en) 1995-07-05 1996-07-05 Therapeutic agents and autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE275968T1 true ATE275968T1 (de) 2004-10-15

Family

ID=10777189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922162T ATE275968T1 (de) 1995-07-05 1996-07-05 Mitteln zur behandlung von auto-immun krankheiten

Country Status (23)

Country Link
US (1) US6287563B1 (de)
EP (1) EP0841939B1 (de)
JP (1) JP4024298B2 (de)
KR (1) KR100452000B1 (de)
CN (1) CN1313150C (de)
AT (1) ATE275968T1 (de)
AU (1) AU724516B2 (de)
CA (1) CA2225788C (de)
CZ (1) CZ298670B6 (de)
DE (1) DE69633393T2 (de)
DK (1) DK0841939T3 (de)
ES (1) ES2229276T3 (de)
GB (1) GB9513733D0 (de)
HK (1) HK1006496A1 (de)
HU (1) HU224248B1 (de)
MX (1) MX9800241A (de)
NO (1) NO319747B1 (de)
NZ (1) NZ311762A (de)
PL (1) PL187266B1 (de)
PT (1) PT841939E (de)
RU (1) RU2203088C2 (de)
SI (1) SI0841939T1 (de)
WO (1) WO1997002045A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
GB9801871D0 (en) * 1998-01-28 1998-03-25 Univ Bristol Therapies
US7914791B1 (en) * 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
HUP0104842A3 (en) * 1998-05-08 2002-12-28 Univ Bristol Bristol Vaccine
US7041296B1 (en) 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
WO2001034175A2 (en) * 1999-11-12 2001-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Dept. Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin b subunit
CA2358061A1 (en) * 2000-09-08 2002-03-08 Stemcell Technologies Inc. Novel antibody compositions for the negative selection of specific rat leukocyte subsets
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2014127258A2 (en) * 2013-02-14 2014-08-21 Cornell University Methods to protect against and treat multiple sclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent

Also Published As

Publication number Publication date
SI0841939T1 (en) 2005-04-30
HUP9900147A2 (hu) 1999-05-28
CZ1298A3 (cs) 1998-06-17
NZ311762A (en) 2001-04-27
PL187266B1 (pl) 2004-06-30
DE69633393T2 (de) 2005-11-10
CN1313150C (zh) 2007-05-02
DK0841939T3 (da) 2005-01-24
PT841939E (pt) 2005-02-28
CA2225788C (en) 2010-09-21
GB9513733D0 (en) 1995-09-06
CA2225788A1 (en) 1997-01-23
RU2203088C2 (ru) 2003-04-27
JPH11508586A (ja) 1999-07-27
AU724516B2 (en) 2000-09-21
MX9800241A (es) 1998-11-30
PL324424A1 (en) 1998-05-25
JP4024298B2 (ja) 2007-12-19
CN1192693A (zh) 1998-09-09
EP0841939B1 (de) 2004-09-15
DE69633393D1 (de) 2004-10-21
ES2229276T3 (es) 2005-04-16
US6287563B1 (en) 2001-09-11
AU6314296A (en) 1997-02-05
EP0841939A1 (de) 1998-05-20
KR100452000B1 (ko) 2004-11-20
NO980005L (no) 1998-03-05
CZ298670B6 (cs) 2007-12-19
HK1006496A1 (en) 1999-03-05
KR19990028578A (ko) 1999-04-15
NO319747B1 (no) 2005-09-12
HU224248B1 (hu) 2005-07-28
WO1997002045A1 (en) 1997-01-23
HUP9900147A3 (en) 1999-11-29
NO980005D0 (no) 1998-01-02

Similar Documents

Publication Publication Date Title
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
DE69316948T2 (de) Lösliche Liganden für CD40
FR2743712B1 (fr) Dispositif d'ancrage d'osteosynthese vertebrale posterieure
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
FR2491334B1 (de)
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE60013636D1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
DE69432517T2 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
Foster St. Mary's Hospital, Manchester
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
ATE167055T1 (de) 4-guanidinobutyramid zur verbesserung des blutkreislaufs
UA9522A (uk) Спосіб лікування аутоімунного тиреоідиту
ATE56874T1 (de) Zubereitung zur behandlung und vorbeugung von diarrhoee bei menschen und tieren und verfahren zu deren herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0841939

Country of ref document: EP